10-Q · May 7, 2026
Syra Health achieved notable improvements in Q1 2026, recording revenue of $2.27 million and a net income of $240,979, marking a significant turnaround from a net loss of $472,265 in the same quarter a year prior. The…
Earnings analysis · 10-Q
SYRA earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Syra Health reported Q2 2026 revenue of $2.394 million, EPS of $0.02, and gross margin of 44.5%, with substantial improvement in profitability versus the prior comparable period. Year-to-date operating cash flow was…
Read full summary
Syra Health reported Q2 2026 revenue of $2.394 million, EPS of $0.02, and gross margin of 44.5%, with substantial improvement in profitability versus the prior comparable period. Year-to-date operating cash flow was $643,183, and management maintained its full-year profitability target for 2026. Sentiment remains neutral because operating performance improved, but management provided no new quantitative revenue or EPS guidance and highlighted revenue-recognition timing risk.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.02
- Gross margin
- 44.5%
What stood out
-
Revenue grew 23% year over year
Q2 2026 revenue was $2.394 million, up 23% year over year, indicating continued top-line growth despite potential contract-milestone timing variability.
-
Margins and EPS improved materially
Gross margin was 44.5% in Q2 2026, materially above the 17.8% reported in Q2 2024, while diluted EPS improved to $0.02 from $(0.21) in the comparable historical period.
-
Returned to profitability
The company reported net income of $250,242 for the period versus a net loss of $63,596 previously, marking a significant improvement in profitability.
-
Positive year-to-date operating cash flow
Operating cash flow was $643,183 for the first six months of 2026, providing positive liquidity generation during the year-to-date period.
-
Controls remained effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control that materially affected, or were reasonably likely to materially affect, reporting.
What to watch
-
Revenue timing may drive volatility
Management stated that revenue-recognition timing and contract milestones may cause quarterly variability; this is material given Q2 revenue of $2.394 million and the company’s relatively small revenue base.
-
Profitability target requires execution
The company maintained its full-year profitability target for 2026, but execution remains a risk because the reported net income was $250,242 and profitability could be sensitive to contract timing and operating expenses.
-
No new risk-factor disclosures
No new quantified risk-factor changes were identified in Item 1A; the filing directs investors to the risk factors in the 2025 Form 10-K and notes that additional unknown risks may materially affect results.
Management's outlook
Management maintained its previously stated target of full-year profitability for 2026. No quantitative revenue or EPS guidance was provided; management noted that revenue-recognition timing and contract milestones may cause quarterly variability.
Earlier filings 4
10-K · April 25, 2026
Syra Health’s 10-K (and follow-up 10-K/A) show a company with declining revenue, limited market valuation and an auditor-level liquidity concern; the company reported fourth-quarter revenue of $1,734,000 and a GAAP…
10-K · March 12, 2026
Syra Health positions itself as an integrated healthcare solutions provider with offerings across behavioral & mental health (flagship app Syrenity), population health, digital health, health education, and workforce…
10-Q · November 12, 2025
Syra Health Corp. reported Q3 2025 revenues of $1,687,971, a decline from $2,253,336 in Q3 2024. The gross margin improved to 32.8% from 29.6% year-over-year, contributing to a narrowed net loss of $(225,902) versus…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.